Sequana Medical N.V.
16
0
2
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
25.0%
4 terminated/withdrawn out of 16 trials
55.6%
-30.9% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Interdialytic Peritoneal UltraFiltration in HemoDialysis Patients
Role: collaborator
International Alfapump Cohort Study
Role: lead
Management of Volume Overload HF Patients by Individual DSR Treatment adJustment-a clinicAl inVestigation of InfusatE2.0
Role: lead
Safety of and Tolerability to a Sodium-free Peritoneal Dialysis Solution
Role: collaborator
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
Role: lead
Safety & Feasibility of DSR TherApy in Heart FAiluRe pAtients With Persistent Congestion
Role: lead
Alfapump Direct Sodium Removal (DSR) Feasibility Study
Role: lead
Optimal Balance Alfapump® System Feasibility Study
Role: lead
ALFApump System Post Marketing Surveillance Registry
Role: lead
Malignant Ascites Alfapump® Study
Role: lead
Alfapump-albumin Replacement Therapy
Role: lead
Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites
Role: lead
A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites
Role: lead
ALFApump System Versus Standard of Care in Ascites Treatment
Role: lead
Investigation Into the Automated Drainage of Recurrent Effusions From the Pleural Space in Thoracic Malignancy.
Role: lead
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
Role: lead
All 16 trials loaded